Small molecule · developed by Kazia Therapeutics
Cantrixil is an agent given by intraperitoneal injection at weekly doses escalated across several dose levels in a Part A dose-escalation study. It is studied in ovarian, fallopian tube and peritoneal neoplasms, alone and then with combination chemotherapy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02903771 | Phase 1 | Ovarian Neoplasms | Completed | KZIA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Updated Oct 18, 2026. Something wrong or missing? Report it on the KZIA page.
See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KZIA catalysts and pipeline →